AL-044 is under clinical development by Alector and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 64% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AL-044’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AL-044 overview

AL-014 is under development for the treatment of Alzheimer’s disease and an orphan neuro indication. The drug candidate is a monoclonal antibody which acts by targeting MS4A4A protein.

Alector overview

Alector is a biotechnology company that develops therapies for immune system to cure neurodegeneration and cancer. The company discovers and develops immune-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. It combines state-of-the-art antibody technology and recent discoveries in neuroimmunology and oncology to fight cancer. Alector also generates and validates antibody drugs that engage key disease-altering and genetically validated neuroimmune targets. The company develops drugs through collaborations with scientists and drug developers. It operates a manufacturing facility in Milpitas, California. Alector is headquartered in South San Francisco, California, the US.

For a complete picture of AL-044’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.